1. RunyonBA. Ascites. In: SchiffL, SchiffER(eds). Diseases of the Liver, 7th edn. Philadelphia: Lippincott Company, 1993: 990.

2. RunyonBA, MontanoAA, AkriviadisEA, et al.The serum‐ascites albumin gradient is superior to the exudate‐transudate concept in the differential diagnosis of ascites. Ann Intern Med1992;117:215. CrossRef

3. D'AmicoG, Garcia‐TsaoG, PagliaroL. Natural history and prognostic indicators of survival in cirrhosis. A systematic review of 118 studies. J Hepatol2006;44:217. CrossRef

4. CummingsS, PapadakisM, MelnickJ, et al.The predictive value of physical examinations for ascites. West J Med1985;142:633.

5. GoldbergBB, GoodmanGA, ClearfieldHR. Evaluation of ascites by ultrasound. Radiology1970;96:15. CrossRef

6. BlackM, FriedmanAC. Ultrasound examination in the patient with ascites. Ann Intern Med1989;110:253. CrossRef

7. RunyonBA. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology2013;57:1651. CrossRef

8. EASL. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol2010;53:397. CrossRef

9. De GottardiA, ThevenotT, SpahrL, et al.Risk of complications after abdominal paracentesis in cirrhotic patients: a prospective study. Clin Gastroenterol Hepatol2009;7:906. CrossRef

10. McVayPA, ToyPT. Lack of increased bleeding after paracentesis and thoracentesis in patients with mild coagulation abnormalities. Transfusion1991;31:164. CrossRef

11. HoefsJC. Serum protein concentration and portal pressure determine the ascitic fluid protein concentration in patients with chronic liver disease. J Lab Clin Med1983;102:260.

12. HenriksenJH. Colloid osmotic pressure in decompensated cirrhosis. A ‘mirror image’ of portal venous hypertension. Scand J Gastroenterol1985;20:170. CrossRef

13. PareP, TalbotJ, HoefsJC. Serum‐ascites albumin concentration gradient: a physiologic approach to the differential diagnosis of ascites. Gastroenterology1983;85:240.

14. HoefsJC. Globulin correction of the albumin gradient: correlation with measured serum to ascites colloid osmotic pressure gradients. Hepatology1992;16:396. CrossRef

15. HirabayashiK, GrahamJ. Genesis of ascites in ovarian cancer. Am J Obstet Gynecol1970;106:492.

16. WitteCL, WitteMH, DumontAE, et al.Lymph protein in hepatic cirrhosis and experimental hepatic and portal venous hypertension. Ann Surg1968;168:567. CrossRef

17. DumontAE, WitteCL, WitteMH. Protein content of liver lymph in patients with portal hypertension secondary to hepatic cirrhosis. Lymphology1975;8:111.

18. HenriksenJH, HornT, ChristoffersenP. The blood‐lymph barrier in the liver. A review based on morphological and functional concepts of normal and cirrhotic liver. Liver1984;4:221. CrossRef

19. FariasAQ, SilvestreOM, Garcia‐TsaoG, et al.Serum B‐type natriuretic peptide in the initial workup of patients with new onset ascites: a diagnostic accuracy study. Hepatology2014;59:1043. CrossRef

20. RunyonBA. Low‐protein‐concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. Gastroenterology1986;91:1343.

21. RunyonBA, HoefsJC. Ascitic fluid chemical analysis before, during and after spontaneous bacterial peritonitis. Hepatology1985;5:257. CrossRef

22. MoraliGA, SnidermanKW, DeitelKM, et al.Is sinusoidal portal hypertension a necessary factor for the development of hepatic ascites?J Hepatol1992;16:249. CrossRef

23. CasadoM, BoschJ, Garcia‐PaganJC, et al.Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology1998;114:1296. CrossRef

24. AbraldesJG, TarantinoI, TurnesJ, et al.Hemodynamic response to pharmacological treatment of portal hypertension and long‐term prognosis of cirrhosis. Hepatology2003;37:902. CrossRef

25. MyersRP, CeriniR, SayeghR, et al.Cardiac hepatopathy: clinical, hemodynamic, and histologic characteristics and correlations. Hepatology2003;37:393. CrossRef

26. GroszmannRJ, WongcharatraweeS. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology2004;39:280. CrossRef

27. RimolaA, Garcia‐TsaoG, NavasaM, et al.Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. J Hepatol2000;32:142. CrossRef

28. RunyonBA, CanawatiHN, AkriviadisEA. Optimization of ascitic fluid culture technique. Gastroenterology1988;95:1351.

29. AkriviadisEA, RunyonBA. Utility of an algorithm in differentiating spontaneous from secondary bacterial peritonitis. Gastroenterology1990;98:127.

30. YoungST, PaulsonEK, WashingtonK, et al.CT of the liver in patients with metastatic breast carcinoma treated by chemotherapy: findings simulating cirrhosis. AJR Am J Roentgenol1994;163:1385. CrossRef

31. SassDA, ClarkK, GrzybickiD, et al.Diffuse desmoplastic metastatic breast cancer simulating cirrhosis with severe portal hypertension: a case of “pseudocirrhosis. Dig Dis Sci2007;52:749. CrossRef

32. RunyonBA, HoefsJC, MorganTR. Ascitic fluid analysis in malignancy‐related ascites. Hepatology1988;8:1104. CrossRef

33. BothCT, de MattosAA, NeumannJ, et al.Flow cytometry in the diagnosis of peritoneal carcinomatosis. Am J Gastroenterol2001;96:1605. CrossRef

34. WeissmanGS, McKinleyMJ, BudmanDR, et al.Flow cytometry. A new technique in the diagnosis of malignant ascites. J Clin Gastroenterol1987;9:599. CrossRef

35. ZuckermanE, LanirA, SaboE, et al.Cancer antigen 125: a sensitive marker of ascites in patients with liver cirrhosis. Am J Gastroenterol1999;94:1613. CrossRef

36. RunyonBA. Malignancy‐related ascites and ascitic fluid “humoral tests of malignancy. J Clin Gastroenterol1994;18:94. CrossRef

37. RissonJR, MacoveiI, LoockM, et al.Cirrhotic and malignant ascites: differential CT diagnosis. Diagn Interv Imaging2012;93:365. CrossRef

38. HillebrandDJ, RunyonBA, YasminehWG, et al.Ascitic fluid adenosine deaminase insensitivity in detecting tuberculous peritonitis in the United States. Hepatology1996;24:1408. CrossRef

39. SanaiFM, BzeiziKI. Systematic review: tuberculous peritonitis–presenting features, diagnostic strategies and treatment. Aliment Pharmacol Ther2005;22:685. CrossRef

40. RiquelmeA, CalvoM, SalechF, et al.Value of adenosine deaminase (ADA) in ascitic fluid for the diagnosis of tuberculous peritonitis: a meta‐analysis. J Clin Gastroenterol2006;40:705. CrossRef

41. BurgessLJ, SwanepoelCG, TaljaardJJ. The use of adenosine deaminase as a diagnostic tool for peritoneal tuberculosis. Tuberculosis (Edinb)2001;81:243. CrossRef

42. SankaranS, WaltAJ. Pancreatic ascites: recognition and management. Arch Surg1976;111:430. CrossRef

43. MunozJN, BoseS. Pancreatic ascites. A case report and review of the literature. Am J Dig Dis1975;20:1178. CrossRef

44. JosephJ, VineyS, BeckP, et al.A prospective study of amylase‐rich pleural effusions with special reference to amylase isoenzyme analysis. Chest1992;102:1455. CrossRef

45. PressOW, PressNO, KaufmanSD. Evaluation and management of chylous ascites. Ann Intern Med1982;96:358. CrossRef

46. AalamiOO, AllenDB, OrganCHJr. Chylous ascites: a collective review. Surgery2000;128:761. CrossRef

47. RectorWGJr. Spontaneous chylous ascites of cirrhosis. J Clin Gastroenterol1984;6:369.

48. Loureiro‐SilvaMR, CadelinaG, GroszmannRJ. Deficit in nitric oxide production in cirrhotic rat livers is located in the sinusoidal and postsinusoidal areas. Am J Physiol Gastrointest Liver Physiol2003;284:G567. CrossRef

49. SchrierRW, ArroyoV, BernardiM, et al.Peripheral arterial vasodilation hypothesis – a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology1988;8:1151. CrossRef

50. GinesP, GuevaraM. Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management. Hepatology2008;48:1002. CrossRef

51. Garcia‐TsaoG, ParikhCR, ViolaA. Acute kidney injury in cirrhosis. Hepatology2008;48:2064. CrossRef

52. PlanasR, MontoliuS, BallesteB, et al.Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol2006;4:1385. CrossRef

53. MooreKP, WongF, GinesP, et al.The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology2003;38:258. CrossRef

54. SalernoF, BorroniG, MoserP, et al.Survival and prognostic factors of cirrhotic patients with ascites: a study of 134 outpatients. Am J Gastroenterol1993;88:514.

55. FogelMR, SawhneyVK, NealA, et al.Diuresis in the ascitic patient: a randomized controlled trial of three regimens. J Clin Gastroenterol1981;3(Suppl 1):73. CrossRef

56. Perez‐AyusoRM, ArroyoV, PlanasR, et al.Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin‐aldosterone system. Gastroenterology1983;84:961.

57. MirouzeD, ZipserRD, ReynoldsTB. Effects of inhibitors of prostaglandin synthesis on induced diuresis in cirrhosis. Hepatology1983;3:50. CrossRef

58. PlanasR, ArroyoV, RimolaA, et al.Acetylsalicylic acid suppresses the renal hemodynamic effect and reduces the diuretic action of furosemide in cirrhosis with ascites. Gastroenterology1983;84:247.

59. Bosch‐MarceM, ClariaJ, TitosE, et al.Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites. Gastroenterology1999;116:1167. CrossRef

60. GuevaraM, AbecasisR, TergR. Effect of celecoxib on renal function in cirrhotic patients with ascites. A pilot study. Scand J Gastroenterol2004;39:385. CrossRef

61. GinesP, ArroyoV, QuinteroE, et al.Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites: results of a randomized study. Gastroenterology1987;93:234.

62. SalernoF, BadalamentiS, IncertiP, et al.Repeated paracentesis and i.v. albumin infusion to treat “tense” ascites in cirrhotic patients: a safe alternative therapy. J Hepatol1987;5:102. CrossRef

63. SolaR, VilaMC, AndreuM, et al.Total paracentesis with dextran 40 vs. diuretics in the treatment of ascites in cirrhosis: a randomized controlled study. J Hepatol1994;20:282. CrossRef

64. StruthersA, KrumH, WilliamsGH. A comparison of the aldosterone‐blocking agents eplerenone and spironolactone. Clin Cardiol2008;31:153. CrossRef

65. AngeliP, Dalla PriaM, DeBeiE, et al.Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites. Hepatology1994;19:72. CrossRef

66. SalernoF, GuevaraM, BernardiM, et al.Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver Int2010;30:937. CrossRef

67. TitoL, GinesP, ArroyoV, et al.Total paracentesis associated with intravenous albumin management of patients with cirrhosis and ascites. Gastroenterology1990;98:146.

68. Fernandez‐EsparrachG, GuevaraM, SortP, et al.Diuretic requirements after therapeutic paracentesis in non‐azotemic patients with cirrhosis. A randomized double‐blind trial of spironolactone versus placebo. J Hepatol1997;26:614. CrossRef

69. SinghV, DhunganaSP, SinghB, et al.Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. J Hepatol2012;56:348. CrossRef

70. MisraVL, VuppalanchiR, JonesD, et al.The effects of midodrine on the natriuretic response to furosemide in cirrhotics with ascites. Aliment Pharmacol Ther2010;32:1044. CrossRef

71. BariK, MinanoC, SheaM, et al.The combination of octreotide and midodrine is not superior to albumin in preventing recurrence of ascites after large‐volume paracentesis. Clin Gastroenterol Hepatol2012;10:1169. CrossRef

72. ArnoldC, HaagK, BlumHE, et al.Acute hemoperitoneum after large‐volume paracentesis. Gastroenterology1997;113:978. CrossRef

73. GrabauCM, CragoSF, HoffLK, et al.Performance standards for therapeutic abdominal paracentesis. Hepatology2004;40:484. CrossRef

74. OelsnerDH, CaldwellSH, ColesM, et al.Subumbilical midline vascularity of the abdominal wall in portal hypertension observed at laparoscopy. Gastrointest Endosc1998;47:388. CrossRef

75. ConnHO. Sudden scrotal edema in cirrhosis: a postparacentesis syndrome. Ann Intern Med1971;74:943. CrossRef

76. GinesA, Fernandez‐EsparrachG, MonescilloA, et al.Randomized trial comparing albumin, dextran‐70 and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology1996;111:1002. CrossRef

77. Ruiz del ArbolL, MonescilloA, JimenezW, et al.Paracentesis‐induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology1997;113:579. CrossRef

78. GinesP, TitoL, ArroyoV, et al.Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology1988;94:1493.

79. PlanasR, GinesP, ArroyoV, et al.Dextran‐70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. Gastroenterology1990;99:1738.

80. Sola‐VeraJ, MinanaJ, RicartE, et al.Randomized trial comparing albumin and saline in the prevention of paracentesis‐induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology2003;37:1147. CrossRef

81. BernardiM, CaraceniP, NavickisRJ, et al.Albumin infusion in patients undergoing large‐volume paracentesis: a meta‐analysis of randomized trials. Hepatology2012;55:1172. CrossRef

82. Garcia‐TsaoG. The transjugular intrahepatic portosystemic shunt for the management of refractory ascites. Nat Clin Pract Gastroenterol Hepatol2006;3:380. CrossRef

83. D'AmicoG, LucaA, MorabitoA, et al.Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta‐analysis. Gastroenterology2005;129:1282. CrossRef

84. SalernoF, CammaC, EneaM, et al.Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta‐analysis of individual patient data. Gastroenterology2007;133:825. CrossRef

85. BureauC, Garcia‐PaganJC, OtalP, et al.Improved clinical outcome using polytetrafluoroethylene‐coated stents for TIPS: results of a randomized study. Gastroenterology2004;126:469. CrossRef

86. BoyerTD, HaskalZJ. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology2005;41:386. CrossRef

87. TrotterJF, SuhockiPV. Incarceration of umbilical hernia following transjugular intrahepatic portosystemic shunt for the treatment of ascites. Liver Transpl Surg1999;5:209. CrossRef

88. GerbesAL, GulbergV. Benefit of TIPS for patients with refractory or recidivant ascites: serum bilirubin may make the difference. Hepatology2005;41:217. CrossRef

89. BuskTM, BendtsenF, MollerS. Cardiac and renal effects of a transjugular intrahepatic portosystemic shunt in cirrhosis. Eur J Gastroenterol Hepatol2013;25:523. CrossRef

90. StanleyMM, OchiS, LeeKK, et al.Peritoneovenous shunting as compared with medical treatment in patients with alcoholic cirrhosis and massive ascites. N Engl J Med1989;321:1632. CrossRef

91. GinesP, ArroyoV, VargasV, et al.Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites. N Engl J Med1991;325:829. CrossRef

92. GinesA, PlanasR, AngeliP, et al.Treatment of patients with cirrhosis and refractory ascites by LeVeen shunt with titanium tip. Comparison with therapeutic paracentesis. Hepatology1995;22:124.

93. DumortierJ, PiantaE, Le DerfY, et al.Peritoneovenous shunt as a bridge to liver transplantation. Am J Transplant2005;5:1886. CrossRef

94. MartinLG. Percutaneous placement and management of the Denver shunt for portal hypertensive ascites. AJR Am J Roentgenol2012;199:W449. CrossRef

95. BellotP, WelkerMW, SorianoG, et al.Automated low flow pump system for the treatment of refractory ascites: a multi‐center safety and efficacy study. J Hepatol2013;58:922. CrossRef

96. BernhoftRA, PellegriniCA, WayLW. Peritoneovenous shunt for refractory ascites: operative complications and long‐term results. Arch Surg1982;117:631. CrossRef

97. ZervosEE, McCormickJ, GoodeSE, et al.Peritoneovenous shunts in patients with intractable ascites: palliation at what price?Am Surg1997;63:157.

98. SantosJ, PlanasR, PardoA, et al.Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety. J Hepatol2003;39:187. CrossRef

99. WongF, WatsonH, GerbesA, et al.Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut2012;61:108. CrossRef

100. FernandezJ, AcevedoJ, CastroM, et al.Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology2012;55:1551. CrossRef

101. TandonP, DelisleA, TopalJE, et al.High prevalence of antibiotic‐resistant bacterial infections among patients with cirrhosis at a US liver center. Clin Gastroenterol Hepatol2012;10:1291. CrossRef

102. ArroyoV, GinesP, GerbesAL, et al.Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology1996;23:164. CrossRef

103. ArroyoV, TerraC, GinesP. Advances in the pathogenesis and treatment of type‐1 and type‐2 hepatorenal syndrome. J Hepatol2007;46:935. CrossRef

104. WongF, GinesP, WatsonH, et al.Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. J Hepatol2010;53:283. CrossRef

105. SersteT, MelotC, FrancozC, et al.Deleterious effects of beta‐blockers on survival in patients with cirrhosis and refractory ascites. Hepatology2010;52:1017. CrossRef

106. Garcia‐PaganJC. Portal hypertension: nonselective beta‐blockers in patients with refractory ascites. Nat Rev Gastroenterol Hepatol2011;8:10. CrossRef

107. BhogalHK, SanyalAJ. Using transjugular intrahepatic portosystemic shunts for complications of cirrhosis. Clin Gastroenterol Hepatol2011;9:936. CrossRef

108. RiggioO, MasiniA, EfratiC, et al.Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. J Hepatol2005;42:674. CrossRef

109. GuevaraM, BaccaroME, RiosJ, et al.Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration. Liver Int2010;30:1137. CrossRef

110. KocharN, TripathiD, IrelandH, et al.Transjugular intrahepatic portosystemic stent shunt (TIPSS) modification in the management of post‐TIPSS refractory hepatic encephalopathy. Gut2006;55:1617. CrossRef

111. FanelliF, SalvatoriFM, RabuffiP, et al.Management of refractory hepatic encephalopathy after insertion of TIPS: long‐term results of shunt reduction with hourglass‐shaped balloon‐expandable stent‐graft. AJR Am J Roentgenol2009;193:1696. CrossRef

112. MaleuxG, VerslypeC, HeyeS, et al.Endovascular shunt reduction in the management of transjugular portosystemic shunt‐induced hepatic encephalopathy: preliminary experience with reduction stents and stent‐grafts. AJR Am J Roentgenol2007;188:659. CrossRef

113. QuirogaJ, SangroB, NunezM, et al.Transjugular intrahepatic portal‐systemic shunt in the treatment of refractory ascites: effect on clinical, renal, humoral, and hemodynamic parameters. Hepatology1995;21:986.

114. LiebermanFL, HidemuraR, PetersRL, et al.Pathogenesis and treatment of hydrothorax complicating cirrhosis with ascites. Ann Intern Med1966;64:341. CrossRef

115. KrokKL, CardenasA. Hepatic hydrothorax. Semin Respir Crit Care Med2012;33:3. CrossRef

116. RubinsteinD, McInnesIE, DudleyFJ. Hepatic hydrothorax in the absence of clinical ascites: diagnosis and management. Gastroenterology1985;88:188. CrossRef

117. SchusterDM, MukundanSJr, SmallW, et al.The use of the diagnostic radionuclide ascites scan to facilitate treatment decisions for hepatic hydrothorax. Clin Nucl Med1998;23:16. CrossRef

118. BhattacharyaA, MittalBR, BiswasT, et al.Radioisotope scintigraphy in the diagnosis of hepatic hydrothorax. J Gastroenterol Hepatol2001;16:317. CrossRef

119. Garcia‐TsaoG. Transjugular intrahepatic portosystemic shunt (TIPS) for the management of refractory ascites in cirrhosis. In: GinesP, ArroyoV, RodesJ, et al. (eds). Ascites and Renal Dysfunction in Liver Disease. Pathogenesis, Diagnosis and Treatment, 2nd edn. Malden, MA: Blackwell, 2005: 251.

120. CardenasA, KelleherT, ChopraS. Review article: hepatic hydrothorax. Aliment Pharmacol Ther2004;20:271. CrossRef

121. TandonP, Garcia‐TsaoG. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis2008;28:26. CrossRef

122. ArvanitiV, D'AmicoG, FedeG, et al.Infections in patients with cirrhosis increase mortality four‐fold and should be used in determining prognosis. Gastroenterology2010;139:1246, 1256. CrossRef

123. WiestR, DasS, CadelinaG, et al.Bacterial translocation to lymph nodes of cirrhotic rats stimulates eNOS‐derived NO production and impairs mesenteric vascular contractility. J Clin Invest1999;104:1223. CrossRef

124. WiestR, Garcia‐TsaoG. Bacterial translocation (BT) in cirrhosis. Hepatology2005;41:422. CrossRef

125. Martin‐LlahiM, GuevaraM, TorreA, et al.Prognostic importance of the cause of renal failure in patients with cirrhosis. Gastroenterology2011;140:488. CrossRef

126. LlachJ, RimolaA, NavasaM, et al.Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: relevance of ascitic fluid protein concentration. Hepatology1992;16:724. CrossRef

127. Garcia‐TsaoG. Spontaneous bacterial peritonitis: a historical perspective. J Hepatol2004;41:522.

128. ChinnockB, AfarianH, MinniganH, et al.Physician clinical impression does not rule out spontaneous bacterial peritonitis in patients undergoing emergency department paracentesis. Ann Emerg Med2008;52:268. CrossRef

129. XiolX, CastellviJM, GuardiolaJ, et al.Spontaneous bacterial empyema in cirrhotic patients: a prospective study. Hepatology1996;23:719. CrossRef

130. FernandezJ, NavasaM, GomezJ, et al.Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology2002;35:140. CrossRef

131. LooNM, SouzaFF, Garcia‐TsaoG. Non‐hemorrhagic acute complications associated with cirrhosis and portal hypertension. Best Pract Res Clin Gastroenterol2013;27:665. CrossRef

132. Gomez‐JimenezJ, RiberaE, GasserI, et al.Randomized trial comparing ceftriaxone with cefonicid for treatment of spontaneous bacterial peritonitis in cirrhotic patients. Antimicrob Agents Chemother1993;37:1587. CrossRef

133. Garcia‐TsaoG. Further evidence against the use of aminoglycosides in cirrhotic patients. Gastroenterology1998;114:612. CrossRef

134. HampelH, BynumGD, ZamoraE, et al.Risk factors for the development of renal dysfunction in hospitalized patients with cirrhosis. Am J Gastroenterol2001;96:2206. CrossRef

135. TandonP, Garcia‐TsaoG. Renal dysfunction is the most important independent predictor of mortality in cirrhotic patients with spontaneous bacterial peritonitis. Clin Gastroenterol Hepatol2011;9:260. CrossRef

136. SortP, NavasaM, ArroyoV, et al.Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med1999;341:403. CrossRef

137. PocaM, ConcepcionM, CasasM, et al.Role of albumin treatment in patients with spontaneous bacterial peritonitis. Clin Gastroenterol Hepatol2012;10:309. CrossRef

138. de AraujoA, de BarrosLA, RossiG, et al.Low‐dose albumin in the treatment of spontaneous bacterial peritonitis: should we change the standard treatment?Gut2012;61:1371. CrossRef

139. FongTL, AkriviadisEA, RunyonBA, et al.Polymorphonuclear cell count response and duration of antibiotic therapy in spontaneous bacterial peritonitis. Hepatology1989;9:423. CrossRef

140. GinesP, RimolaA, PlanasR, et al.Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double‐blind, placebo‐controlled trial. Hepatology1990;12:716. CrossRef

141. BauerTM, FolloA, NavasaM, et al.Daily norfloxacin is more effective than weekly rufloxacin in prevention of spontaneous bacterial peritonitis recurrence. Dig Dis Sci2002;47:1356. CrossRef

142. SalernoF, CazzanigaM, MerliM, et al.Diagnosis, treatment and survival of patients with hepatorenal syndrome: a survey on daily medical practice. J Hepatol2011;55:1241. CrossRef

143. MehtaRL, KellumJA, ShahSV, et al.Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care2007;11:R31. CrossRef

144. WongF, NadimMK, KellumJA, et al.Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut2011;60:702. CrossRef

145. TsienCD, RabieR, WongF. Acute kidney injury in decompensated cirrhosis. Gut2013;62:131. CrossRef

146. BelcherJM, Garcia‐TsaoG, SanyalAJ, et al.Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology2013;57:753. CrossRef

147. BelcherJM, ParikhCR, Garcia‐TsaoG. Acute kidney injury in patients with cirrhosis: perils and promise. Clin Gastroenterol Hepatol2013;11:1550. CrossRef

148. VernaEC, BrownRS, FarrandE, et al.Urinary neutrophil gelatinase‐associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis. Dig Dis Sci2012;57:2362. CrossRef

149. FagundesC, PepinMN, GuevaraM, et al.Urinary neutrophil gelatinase‐associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis. J Hepatol2012;57:267. CrossRef

150. SalernoF, GerbesA, GinesP, et al.Diagnosis, prevention and treatment of the hepatorenal syndrome in cirrhosis. A consensus workshop of the international ascites club. Gut2007;56:1310.

151. GinesA, EscorsellA, GinesP, et al.Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology1993;105:229.

152. AlessandriaC, OzdoganO, GuevaraM, et al.MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology2005;41:1282. CrossRef

153. Ruiz‐del‐ArbolL, MonescilloA, ArocenaC, et al.Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology2005;42:439. CrossRef

154. DavisCL. Impact of pretransplant renal failure: when is listing for kidney‐liver indicated?Liver Transpl2005;11:S35. CrossRef

155. WiesnerR, EdwardsE, FreemanR, et al.Model for end‐stage liver disease (MELD) and allocation of donor livers. Gastroenterology2003;124:91. CrossRef

156. AngeliP, GinesP. Hepatorenal syndrome, MELD score and liver transplantation: an evolving issue with relevant implications for clinical practice. J Hepatol2012;57:1135. CrossRef

157. RimolaA, GavalerJS, SchadeRR, et al.Effects of renal impairment on liver transplantation. Gastroenterology1987;93:148.

158. GonwaTA, KlintmalmGB, LevyM, et al.Impact of pretransplant renal function on survival after liver transplantation. Transplantation1995;59:361. CrossRef

159. NairS, VermaS, ThuluvathPJ. Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology2002;35:1179. CrossRef

160. GonwaTA, McBrideMA, AndersonK, et al.Continued influence of preoperative renal function on outcome of orthotopic liver transplant (OLTX) in the US: where will MELD lead us?Am J Transplant2006;6:2651. CrossRef

161. RestucciaT, OrtegaR, GuevaraM, et al.Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case‐control study. J Hepatol2004;40:140. CrossRef

162. Garcia‐MartinezR, CaraceniP, BernardiM, et al.Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology2013;58:1836. CrossRef

163. GluudLL, ChristensenK, ChristensenE, et al.Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology2010;51:576. CrossRef

164. SanyalAJ, BoyerT, Garcia‐TsaoG, et al.A randomized, prospective, double‐blind, placebo‐controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology2008;134:1360. CrossRef

165. SharmaP, KumarA, ShramaBC, et al.An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol2008;103:1689. CrossRef

166. SinghV, GhoshS, SinghB, et al.Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol2012;56:1293. CrossRef

167. AngeliP, VolpinR, GerundaG, et al.Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology1999;29:1690. CrossRef

168. WongF, PanteaL, SnidermanK. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology2004;40:55. CrossRef

169. CavallinM, KamathPS, MerliM, et al.Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. Hepatology2015. Epub ahead of print. doi: 10.1002/hep.27709.

170. VelezJC, NietertPJ. Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: a pooled analysis of clinical trials. Am J Kidney Dis2011;58:928. CrossRef

171. OrtegaR, GinesP, UrizJ, et al.Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology2002;36:941. CrossRef

172. GuevaraM, GinesP, BandiJC, et al.Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology1998;28:416. CrossRef

173. BrensingKA, TextorJ, PerzJ, et al.Long‐term outcome after transjugular intrahepatic portosystemic stent‐shunt in non‐transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut2000;47:288. CrossRef

174. MitznerSR, StangeJ, KlammtS, et al.Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective randomized, controlled clinical trial. Liver Transpl2000;6:277. CrossRef

175. BanaresR, NevensF, LarsenFS, et al.Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute‐on‐chronic liver failure: the RELIEF trial. Hepatology2013;57:1153. CrossRef